A recent study indicates that patients who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end traditional lifestyle plans.
Findings released in a prominent health publication shows that while overweight individuals frequently drop a large proportion of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying these treatments need to be aware of the risk of fast weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to original weight within about a year and a half.
Comparing Therapies
The study, which reviewed 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone usually experience a less rapid weight regain—around 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Experts propose the mechanism of the injections explains the heightened rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to hunger is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
Health authorities recommend the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of weight regain, the therapy should be considered life-long.
This view is reinforced by pharmaceutical companies, who state that the results "underscore the chronic character of excess weight," similar to managing conditions like hypertension.
User Accounts
Users who have stopped the jabs explain a intense resurgence of cravings.
"It felt as if a trigger that goes on and you're instantly extremely hungry," said an individual.
This difficulty is exacerbated if individuals have not established permanent dietary or behavioural modifications during treatment.
Widespread Interest
Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, researchers caution that while the jabs are potent agents for weight loss, they are not a standalone cure and lasting health benefits likely depends on integrated behavioural changes.
